A retrospective study showed that breast cancer patients with high levels of ER-α36 experience less benefit from tamoxifen than those with low levels of ERα-36 expression, and Erα-36 expression is significantly correlated with Her2/Neu expression. The gene discussed is ERBB2; the disease is breast cancer.